Treatment of murine fusariosis with SCH 56592.
Doses of 10 to 100 mg of the azole antifungal agent SCH 5692/kg of body weight/day were studied in immunocompetent mice as therapy for systemic infection by Fusarium solani. Treatment was begun 1 h after intravenous infection and continued daily for 4 or 13 doses. Prolongation of survival and organ clearance were dependent on both the dose and the duration of SCH 56592 therapy, with the best results seen at 50 and 100 mg/kg/day. The results at the highest doses of SCH 56592 used (50 or 100 mg/kg/day) were comparable to those obtained with amphotericin B at 1 mg/kg/day. SCH 56592 has potential for therapy of systemic infections caused by F. solani.
Lozano-Chiu
M
M
Department of Internal Medicine, University of Texas Medical School, Houston 77030, USA. mchiu@heart.med.uth.tmc.edu
Arikan
S
S
Paetznick
V L
VL
Anaissie
E J
EJ
Loebenberg
D
D
Rex
J H
JH
D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D015169:Colony Count, Microbial; D005670:Fusarium; D007668:Kidney / Q000382:microbiology; D008297:Male; D051379:Mice; D009181:Mycoses / Q000188:drug therapy* / Q000382:microbiology; D014230:Triazoles / Q000627:therapeutic use*
D000935:Antifungal Agents; D014230:Triazoles; C101425:posaconazole